← Theravance Biopharma, Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying Value | $344.7m | $89.0m | $378.0m | $58.1m | $81.5m | $90.0m | $298.2m | $39.5m | $37.8m | $167.8m | |
| Inventory, Net | $12.2m | $16.8m | $0 | — | — | — | — | — | — | — | |
| Assets, Current | $528.5m | $378.7m | $532.8m | $338.5m | $393.3m | $249.9m | $353.5m | $133.5m | $161.1m | $418.5m | |
| Property, Plant and Equipment, Net | $8.5m | $10.2m | $13.2m | $12.6m | $16.4m | $13.7m | $11.9m | $9.1m | $7.4m | $5.9m | |
| Operating Lease, Right-of-Use Asset | — | — | — | $46.6m | $43.3m | $39.7m | $40.1m | $36.3m | $28.4m | $24.4m | |
| Other Assets, Noncurrent | $1.9m | $1.9m | $1.5m | $1.6m | $2.5m | $3.2m | $6.9m | $8.1m | $12.3m | $24.9m | |
| Additional Financial Items | |||||||||||
| Accounts Receivable, after Allowance for Credit Loss, Current | $646k | $2.3m | $620k | — | — | — | — | — | — | — | |
| Assets | $639.3m | $441.4m | $560.2m | $408.8m | $469.1m | $374.8m | $607.4m | $382.0m | $354.2m | $485.6m | |
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Operating Lease, Liability, Current | — | — | — | $7.8m | $9.9m | $503k | $6.8m | $3.9m | $10.7m | $10.9m | |
| Accounts Payable, Current | $1.7m | $5.9m | $9.0m | $4.8m | $6.8m | $3.1m | $1.6m | $1.5m | $2.2m | $2.6m | |
| Operating Lease, Liability, Noncurrent | — | — | — | $47.7m | $47.2m | $52.7m | $45.4m | $45.2m | $39.1m | $31.8m | |
| Deferred Revenue, Current | $152k | $125k | — | — | — | — | — | — | — | — | |
| Liabilities, Current | $49.3m | $62.6m | $98.6m | $111.7m | $123.6m | $58.6m | $28.7m | $24.8m | $32.1m | $38.3m | |
| Other Liabilities, Noncurrent | $13.1m | $36.3m | $24.8m | $21.3m | $1.8m | $2.4m | $1.7m | $5.9m | $1.9m | $313k | |
| Long-term Debt | — | — | $454.4m | $455.0m | $619.2m | $616.3m | — | $0 | — | — | |
| Deferred Tax Liabilities, Net | — | — | — | — | — | — | $1.9m | $5.1m | — | — | |
| Stockholders’ equity: | |||||||||||
| Common Stock, Value, Issued | $1k | $1k | $1k | $1k | $1k | $1k | $1k | — | — | $1k | |
| Additional Paid in Capital | $862.7m | $913.6m | $960.7m | $1.0b | $1.2b | $1.4b | $1.3b | $1.1b | $1.1b | $1.2b | |
| Retained Earnings (Accumulated Deficit) | ($512.2m) | ($797.7m) | ($1.0b) | ($1.2b) | ($1.5b) | ($1.7b) | ($853.9m) | ($909.1m) | ($965.5m) | ($859.6m) | |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | ($253k) | ($733k) | ($166k) | $145k | $47k | — | ($15k) | ($65k) | $7k | $61k | |
| Stockholders' Equity Attributable to Parent | $350.2m | $115.2m | ($51.6m) | ($223.8m) | ($303.8m) | ($338.6m) | $441.8m | $213.0m | $175.5m | $296.7m | |
| Liabilities and Equity | $639.3m | $441.4m | $560.2m | $408.8m | $469.1m | $374.8m | $607.4m | $382.0m | $354.2m | $485.6m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.